Navigation Links
Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
Date:5/26/2011

NEW YORK, May 26, 2011 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health LLC and Respira Health LLC, a privately held predictive genetic testing company focused on oncology, announced today a new agreement under which NeoGenomics Laboratories will offer Signal Genetics' new gene expression profile test for Multiple Myeloma (MyPRS™) to pathologists and hospital-based hematologists/oncologists nationwide.

Myeloma Prognostic Risk Signature™ (MyPRS) offers the most detailed expression profiling information for multiple myeloma patients available on the market. MyPRS analyzes and applies a proprietary algorithm to a defined number of relevant genes to determine the gene expression profile associated with the patient's condition. The gene expression profiling behind MyPRS allows physicians to gain a predictive view of their patient's prognosis, enabling truly personalized treatment options.  The technology has been published in more than 70 peer-reviewed scientific journals and is powered by the world's largest outcomes database for multiple myeloma patients.

Douglas VanOort, Chairman and CEO of NeoGenomics, stated, "Our new partnership with Signal Genetics provides broad access to this important new prognostic marker for patients with Multiple Myeloma and complements our strategy of bringing novel products to our customers.  The agreement also provides NeoGenomics a right of first negotiation to market any genomic and transcriptomic-based diagnostic tests developed and/or introduced by Signal in the future to pathologists and hospital-based oncologists/hematologists."  

Under the terms of the agreement, the MyPRS test  will be performed at Signal Genetics' CLIA-certified laboratory based in Little Rock, Arkansas and the test results will be incorporated into NeoGenomics' test reports and provided to their customers along with other ancillary diagnostic tests.  

According to Joe Hernandez, CEO of Signal Genetics, "This Agreement represents another important milestone in our commercialization plan for our Myeloma Prognostic Risk Signature (MyPRS) test.  NeoGenomics is an industry leader in serving the needs of pathologists and hospital-based hematologists/oncologists.  Further, it expands our partnerships with key players in the molecular diagnostics marketplace and provides potential vehicles by which to commercialize additional products currently in our pipeline.  MyPRS is currently available nationally to community-based hematologists and medical oncologists through a similar arrangement with Caris Life Sciences."

About Signal Genetics

Signal Genetics, the parent company of Myeloma Health and Respira Health, is a privately held predictive genetic testing company focused on helping cancer patients. The goal of Signal Genetics is to provide cancer patients and their physicians with novel and innovative insights into their disease, including predictive outcome of disease stage, odds of relapse, and the optimal treatment regimen based on their specific genetic expression profile. Additional information is available at www.signalgenetics.com.

About NeoGenomics

NeoGenomics Laboratories, Inc. operates a network of high-complexity CLIA–certified clinical laboratories that specialize in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.  The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.  


'/>"/>
SOURCE Signal Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area
2. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
3. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
4. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
5. Device Blocking Stomach Nerve Signals Shows Promise in Obesity
6. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
7. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
8. St. Jude Finds Signaling System That Halts the Growth of a Childhood Brain Cancer
9. AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling
10. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
11. USP Hospitales of Spain to Offer Interleukin Genetics Heart Health Test Throughout Its Hospital Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):